Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4874MR)

This product GTTS-WQ4874MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4874MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9025MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ11960MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ2922MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ15239MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ12755MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ15873MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ5374MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ6237MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW